Upadacitinib (Rinvoq) therapy yields favorable outcomes in people with Crohn disease (CD). Patients with ulcerative colitis taking tofacitinib or biologics do not have an increased risk of MI or stroke. The biosimilars were as effective in treating inflammatory bowel disease.